Clinical trials: Cytokine
Covid19, ARDS
Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS
ExoFlo, Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Allograft Product, Infusion Treatment is currently being studied in Protocol DB-EF-PhaseIII-0001 in patients COVID-19 associated moderate to severe acute…
- Conditions
- Covid19, ARDS, Hypoxia, Cytokine Storm
- Trial name
- NCT04657458
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight
The purpose of this trial is to study the effect of megestrol acetate in the gain of body weight in patients with severe Chronic obstructive pulmonary disease in order to improve the survival of the patients.
- Trial name
- NCT00507949
- Testing
- Megestrol acetate
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Rottapharm Spain
Microbiome, Cytokines
Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis
This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to…
- Conditions
- Microbiome, Cytokines, Plaque, Gingivitis
- Trial name
- NCT07501455
- Testing
- Distilled Water, Marketed Comparator 1, Marketed Comparator 2
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Kenvue Brands LLC
Psoriasis
Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis
Psoriasis is a chronic, inflammatory skin condition driven by the immune system, marked by red, scaly plaques that commonly affect the scalp and nails.
- Trial name
- NCT06640114
- Testing
- Efferon CT
- Where
- 2 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Efferon JSC
Hepatocellular Carcinoma
A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA
A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of Autologous Cytokine-Induced Killer (CIK) Cell for Patients with Hepatocellular Carcinoma (HCC) after Transarterial Chemoembolization (TACE), Percutaneous…
- Trial name
- NCT03124498
- Testing
- CIK Cell
- Volunteers
- 55 people
- Sponsor
- Chuan An Biotechnology Co., Ltd.
Carcinoma, Renal Cell
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 [NCT00076011] study to estimate the 5-year survival rate in subjects with…
- Trial name
- NCT01056263
- Testing
- axitinib: observational study
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Impression Cytology
Assessment of Levels of Intracellular Cytokines and Markers in Cells Recovered From the Anterior Eye (Phase 4)
This is a single-visit, non-randomized, bilateral, cross-sectional study. In a pre-screening assessment, potential subjects will be invited to complete a web-based questionnaire that is validated to determine symptomatic vs…
- Trial name
- NCT04186858
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05468307
- Testing
- Membrane Bound Cytokine Modified TIL
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Juncell Therapeutics
Soft Tissue Sarcoma
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in advanced or metastatic soft-tissue sarcoma…
- Trial name
- FIBROSARC (NCT04650984)
- Testing
- Onfekafusp alfa, Doxorubicin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 102 people
- Sponsor
- Philogen S.p.A.
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Merus B.V.
Safety and Tolerability in Healthy Subjects
A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects
This study is a single-center, randomized, single-blind, placebo (PBO)-controlled, multiple-dose study to characterize the safety, tolerability, PK, and PD of IV BNZ-1 administered to healthy adult subjects once weekly (QW) for 4…
- Trial name
- NCT03239379
- Testing
- BNZ132-1-40
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bioniz Therapeutics
Healthy
A First-in-Human Study of BNZ132-1-40
This is an open-label, single ascending dose study to characterize the safety and PK/PD profile of IV BNZ132-1-40, a novel peptide inhibitor of multiple cytokines in the IL-2 family.
- Trial name
- NCT03046459
- Testing
- BNZ132-1-40
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bioniz Therapeutics
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb